BCL11A and cancer: Choi et al. findings could support previous hypothesis, showing that the inhibition of BCL11A and HDAC1/2 effectively reprogramming basal like cancer cells into luminal A cells, increasing ER expression and leading to tamoxifen sensitivity (Choi et al.2022).